Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.


TSX:MDP - Post by User

Bullboard Posts
Comment by TheRock07on Jul 15, 2016 11:13am
220 Views
Post# 25055882

RE:RE:Knight Therapeutics acquires minor stake in Pediapharm

RE:RE:Knight Therapeutics acquires minor stake in PediapharmGoodmans due diligence is about as good as you can get and Knight is the best possible partner to have, with all that experience and over $650 million in cash.

Eventually, PDP will be taken over by Knight.

Its an ideal proxy for how he built Paladin and sold it for $1.5 billion.....buying small pharmas with diversified drugs in safe markets and with cash on the balance sheet.

By my count PDP now have about $11 million in cash and liquid investments and will soon have more than 8 niche drugs in commercial sale increasing sales to $10 million within 18 months.

Very undervalued and unknown... What more can you ask for
Bullboard Posts